Patrik Renblad
Director of Finance/CFO en CANTARGIA AB .
Perfil
Patrik Renblad is currently the Chief Financial Officer at Cantargia AB since 2023.
Prior to this, he was the Chief Financial Officer at SynAct Pharma AB from 2022 to 2023.
He also worked as a Finance Director-R&D at LEO Pharma A.
Mr. Renblad is a graduate of the University of Lund.
Cargos activos de Patrik Renblad
Empresas | Cargo | Inicio |
---|---|---|
CANTARGIA AB | Director of Finance/CFO | 15/06/2023 |
Antiguos cargos conocidos de Patrik Renblad.
Empresas | Cargo | Fin |
---|---|---|
SYNACT PHARMA AB | Director of Finance/CFO | 15/05/2023 |
LEO Pharma A/S
LEO Pharma A/S Pharmaceuticals: MajorHealth Technology LEO Pharma A/S develops, manufactures and markets drugs within the area of dermatology and critical care medicine. It supplies medicines to patients suffering from skin infections and diseases such as psoriasis and eczema, thrombosis, kidney disease and cancer. The company was founded by August Kongsted and Anton Antons in 1908 and is headquartered in Ballerup, Denmark. | Corporate Officer/Principal | - |
Formación de Patrik Renblad.
University of Lund | Graduate Degree |
Experiencias
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
Empresas relacionadas
Empresas cotizadas | 2 |
---|---|
CANTARGIA AB | Health Technology |
SYNACT PHARMA AB | Health Technology |
Empresas privadas | 1 |
---|---|
LEO Pharma A/S
LEO Pharma A/S Pharmaceuticals: MajorHealth Technology LEO Pharma A/S develops, manufactures and markets drugs within the area of dermatology and critical care medicine. It supplies medicines to patients suffering from skin infections and diseases such as psoriasis and eczema, thrombosis, kidney disease and cancer. The company was founded by August Kongsted and Anton Antons in 1908 and is headquartered in Ballerup, Denmark. | Health Technology |
- Bolsa de valores
- Insiders
- Patrik Renblad